Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Renal Failure Chronic Kidney Disease Anemia |
Drug: peginesatide |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease |
- Proportion of Participants With Mean Hemoglobin in the Target Range of 10.0-12.0 Grams Per Deciliter (g/dL) After Dosing Guideline Change [ Time Frame: Up to 54 months ] [ Designated as safety issue: No ]
| Enrollment: | 81 |
| Study Start Date: | September 2006 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Peginesatide |
Drug: peginesatide
Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
Other Names:
|
Detailed Description:
Anemia associated with chronic kidney disease is due to several factors, primarily the inability of the diseased kidneys to produce adequate amounts of endogenous erythropoietin. Ancillary factors include the shortened lifespan of red blood cells, iron and other nutritional deficiencies, infection, and inflammation. The presence and severity of anemia are related to the duration and extent of kidney failure. Anemia is associated with increased mortality, increased likelihood of hospitalization, reduced cognitive function, and increased left ventricular hypertrophy and heart failure.
Erythropoiesis stimulating agents have been established as a treatment for anemia in subjects with chronic kidney disease, and have improved the management of anemia over alternatives such as transfusion. Peginesatide is a parenteral formulation developed for the treatment of anemia associated with chronic kidney disease. Peginesatide binds to and activates the human erythropoietin receptor, and stimulates erythropoiesis in human red cell precursors in a manner similar to other known erythropoiesis-stimulating agents (ESAs).
Study participants had received at least 24 weeks of peginesatide dosing in a previous Affymax-sponsored study (NCT00228449) and were to receive doses of peginesatide for approximately 54 months. However, the Sponsor ended the study early.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local, and national guidelines
- Males or females ≥ 18 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 4 weeks prior to study drug administration, and must be willing to continue contraception until at least 4 weeks after the last dose of study drug.
- Participant who has received at least 24 weeks of peginesatide dosing in a previous Affymax-sponsored study
- One hemoglobin value of > 10.0 g/dL in the 4 weeks prior to study drug administration
Exclusion Criteria:
- Known intolerance to peginesatide or pegylated products
- History of antibodies to any erythropoiesis stimulating agent (ESA) or history of pure red cell aplasia (PRCA)
- High likelihood of early withdrawal or interruption of the study (e.g., participant suffers from any clinically significant medical disease or condition that may, in the Investigator's opinion, interfere with safety, assessment, or follow-up of the participant)
- Anticipated life expectancy < 18 months
- Receipt of any ESA other than peginesatide at any time after participant enrollment in the previous Affymax-sponsored study
Contacts and Locations| United States, Arkansas | |
| Research Facility | |
| Pine Bluff, Arkansas, United States, 71603 | |
| United States, California | |
| Research Facility | |
| Mountain View, California, United States, 94041 | |
| United States, Florida | |
| Research Facility | |
| Lauderdale Lakes, Florida, United States, 33313 | |
| Research Facility | |
| Pembroke Pines, Florida, United States, 33028 | |
| United States, Louisiana | |
| Research Facility | |
| Shreveport, Louisiana, United States, 71101 | |
| United States, Michigan | |
| Research Facility | |
| Detroit, Michigan, United States, 48202 | |
| United States, Ohio | |
| Research Facility | |
| Canton, Ohio, United States, 44718 | |
| United States, Tennessee | |
| Research Facility | |
| Nashville, Tennessee, United States, 37205 | |
| United States, Texas | |
| Research Facility | |
| San Antonio, Texas, United States, 78215 | |
| Study Director: | Vice President, Clinical Development | Affymax |
More Information
No publications provided
| Responsible Party: | Affymax |
| ClinicalTrials.gov Identifier: | NCT00372489 History of Changes |
| Other Study ID Numbers: | AFX01-09 |
| Study First Received: | September 5, 2006 |
| Results First Received: | April 26, 2012 |
| Last Updated: | June 22, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Affymax:
|
anemia chronic kidney disease CKD chronic renal failure CRF dialysis erythropoietin EPO erythropoiesis stimulating agent ESA |
Hematide™ hemodialysis hemoglobin Hb Hgb Omontys peginesatide red blood cell red blood cell production |
Additional relevant MeSH terms:
|
Anemia Kidney Diseases Kidney Failure, Chronic Renal Insufficiency Renal Insufficiency, Chronic Hematologic Diseases |
Urologic Diseases Hematinics Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013